Larvol Delta - Study-of-Olaparib-Plus-Pembrolizumab-Versus-Chemotherapy-Plus-Pembrolizumab-After-Induction-With-FirstLine-Chemotherapy-Plus-Pembrolizumab-in-Triple-Negative-Breast-Cancer-TNBC-MK7339009KEYLYNK009

carboplatin - Generic mfg.

Keytruda (pembrolizumab) - Merck (MSD)

Lynparza (olaparib) - Merck (MSD), AstraZeneca

http://clinicaltrials.gov/ct2/show/NCT04191135

Sep 15, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next